What about study enrollment?

Last updated: 3.16.2020

Study teams should halt or delay subject enrollment if appropriate based on COVID-19-related public health recommendations, facility requirements, study team availability, and/or subject populations considered at high risk for susceptibility to COVID-19. These kinds of temporary halts to study enrollment do NOT need to be reported to the IRB. Suspensions of study enrollment due to non-COVID-19-related safety concerns of DSMB/DMC findings must still be reported to the IRB per usual.